Repligen | RGEN - Assets



Repligen reported $2.85B in Assets for its fiscal quarter ending in March of 2025.


Assets Change Date
Agilent USD 12.23B 68M Jul/2025
Align Technology USD 6.22B 116.27M Jun/2025
Bio Techne USD 2.56B 86.39M Jun/2025
BioMarin Pharmaceutical USD 7.46B 309.33M Jun/2025
Bristol-Myers Squibb USD 94.68B 2.25B Jun/2025
Bruker USD 6.34B 406.7M Jun/2025
Charles River Laboratories USD 7.56B 21.82M Jun/2025
Danaher USD 81.62B 2.5B Jun/2025
Dentsply International USD 6.07B 19M Jun/2025
Exact Sciences USD 5.8B 86.29M Jun/2025
General Electric Aerospace USD 125.26B 1.13B Jun/2025
Henry Schein USD 10.91B 426M Jun/2025
Illumina USD 6.09B 95M Jun/2025
IQVIA Holdings USD 28.63B 1.31B Jun/2025
Mettler Toledo International USD 3.4B 165.79M Jun/2025
Myriad Genetics USD 1.01B 21.5M Mar/2025
Pfizer USD 206.1B 1.93B Jun/2025
Repligen USD 2.85B 22.48M Mar/2025
Revvity USD 12.36B 2.06M Jun/2025
Standard Biotools USD 556.96M 55.38M Jun/2025
Thermo Fisher Scientific USD 101.23B 2.19B Jun/2025
Waters USD 4.72B 126.5M Jun/2025
West Pharmaceutical Services USD 3.95B 334.6M Jun/2025